137 related articles for article (PubMed ID: 17896839)
21. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.
Hainsworth JD
Arthritis Res Ther; 2003; 5 Suppl 4(Suppl 4):S12-6. PubMed ID: 15180892
[TBL] [Abstract][Full Text] [Related]
22. [Anti-CD20 therapy in rheumatoid arthritis].
Roll P; Tony HP
Z Rheumatol; 2009 Jul; 68(5):370-9. PubMed ID: 19449019
[TBL] [Abstract][Full Text] [Related]
23. Certolizumab pegol: in rheumatoid arthritis.
Duggan ST; Keam SJ
BioDrugs; 2009; 23(6):407-17. PubMed ID: 19894782
[TBL] [Abstract][Full Text] [Related]
24. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
25. Long-term effects of rituximab in rheumatoid arthritis: clinical, biologic, and pharmacogenetic aspects.
Quartuccio L; Lombardi S; Fabris M; Masolini P; Saracco M; Pellerito R; De Vita S
Ann N Y Acad Sci; 2009 Sep; 1173():692-700. PubMed ID: 19758217
[TBL] [Abstract][Full Text] [Related]
26. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
27. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.
Bingham CO; Looney RJ; Deodhar A; Halsey N; Greenwald M; Codding C; Trzaskoma B; Martin F; Agarwal S; Kelman A
Arthritis Rheum; 2010 Jan; 62(1):64-74. PubMed ID: 20039397
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells.
De Vita S; Zaja F; Sacco S; De Candia A; Fanin R; Ferraccioli G
Arthritis Rheum; 2002 Aug; 46(8):2029-33. PubMed ID: 12209504
[TBL] [Abstract][Full Text] [Related]
29. Safety of rituximab in rheumatoid arthritis.
Covelli M; Sarzi-Puttini P; Atzeni F; Macchioni P
Reumatismo; 2010; 62(2):101-6. PubMed ID: 20657886
[TBL] [Abstract][Full Text] [Related]
30. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy.
Walsh CA; Fearon U; FitzGerald O; Veale DJ; Bresnihan B
Clin Exp Rheumatol; 2008; 26(4):656-8. PubMed ID: 18799100
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab (MabThera) as treatment of active rheumatoid arthritis].
El Fassi D; Nielsen CH; Bendtzen K
Ugeskr Laeger; 2006 Nov; 168(47):4079-81. PubMed ID: 17134602
[TBL] [Abstract][Full Text] [Related]
32. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
34. Tabalumab, an anti-BAFF monoclonal antibody, in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors.
Genovese MC; Fleischmann RM; Greenwald M; Satterwhite J; Veenhuizen M; Xie L; Berclaz PY; Myers S; Benichou O
Ann Rheum Dis; 2013 Sep; 72(9):1461-8. PubMed ID: 23268367
[TBL] [Abstract][Full Text] [Related]
35. Rituximab therapy in rheumatoid arthritis in daily practice.
Assous N; Gossec L; Dieudé P; Meyer O; Dougados M; Kahan A; Allanore Y
J Rheumatol; 2008 Jan; 35(1):31-4. PubMed ID: 18176989
[TBL] [Abstract][Full Text] [Related]
36. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years.
Strand V; Balbir-Gurman A; Pavelka K; Emery P; Li N; Yin M; Lehane PB; Agarwal S
Rheumatology (Oxford); 2006 Dec; 45(12):1505-13. PubMed ID: 17062648
[TBL] [Abstract][Full Text] [Related]
37. Improvement of refractory rheumatoid arthritis after depletion of B cells.
Kneitz C; Wilhelm M; Tony HP
Scand J Rheumatol; 2004; 33(2):82-6. PubMed ID: 15163108
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment.
Higashida J; Wun T; Schmidt S; Naguwa SM; Tuscano JM
J Rheumatol; 2005 Nov; 32(11):2109-15. PubMed ID: 16265687
[TBL] [Abstract][Full Text] [Related]
39. What is the place of recently approved T cell-targeted and B cell-targeted therapies in the treatment of rheumatoid arthritis? Lessons from global clinical trials.
Smolen JS
J Rheumatol Suppl; 2007 Jul; 79():15-20. PubMed ID: 17611974
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]